These data are in line with a recent study investigating the role of IDH1/2 mutations in 4930 AML patients that reported a significantly better RFS and OS for patients with IDH2 mutations affecting residue R172 [63] as compared with IDHwt patients of the ELN 2017 intermediate and high-risk subgroups. Here, IDH1 is linked to acute myeloid leukemia.